F Crofts

Summary

Affiliation: Aventis Pharma

Publications

  1. ncbi request reprint Different embryo-fetal toxicity effects for three VLA-4 antagonists
    F Crofts
    Department of Drug Safety Evaluation, Aventis Inc, Bridgewater, New Jersey 08807, USA
    Birth Defects Res B Dev Reprod Toxicol 71:55-68. 2004
  2. ncbi request reprint Critical period for a teratogenic VLA-4 antagonist: Developmental effects and comparison of embryo drug concentrations of teratogenic and non-teratogenic VLA-4 antagonists
    F Crofts
    Department of Drug Safety Evaluation, Aventis Inc, Bridgewater, New Jersey 08807, USA
    Birth Defects Res B Dev Reprod Toxicol 71:69-79. 2004

Collaborators

Detail Information

Publications2

  1. ncbi request reprint Different embryo-fetal toxicity effects for three VLA-4 antagonists
    F Crofts
    Department of Drug Safety Evaluation, Aventis Inc, Bridgewater, New Jersey 08807, USA
    Birth Defects Res B Dev Reprod Toxicol 71:55-68. 2004
    ..Objectives of the current study were to assess and compare the teratogenic potential of three VLA-4 antagonists...
  2. ncbi request reprint Critical period for a teratogenic VLA-4 antagonist: Developmental effects and comparison of embryo drug concentrations of teratogenic and non-teratogenic VLA-4 antagonists
    F Crofts
    Department of Drug Safety Evaluation, Aventis Inc, Bridgewater, New Jersey 08807, USA
    Birth Defects Res B Dev Reprod Toxicol 71:69-79. 2004
    ..Objectives of the current study were to determine the critical period for inducing IVL984-related embryo-fetal effects, and to test the hypothesis that these effects were due to higher embryo drug concentrations...